Table 1

Characteristics of participants (n=27)

Age at vaccination (years)Vaccine setting
125Community24
136Inpatient3
148
158
Ethnicity Gender
White21Male16
Asian3Female11
Black British/black dual ethnicity3
Underlying diagnoses
Congenital neuromuscular condition including muscular dystrophy/SMA4 (15%)
Cerebral palsy (non-ambulant)8 (30%)
Metabolic/genetic conditions with associated neurodisability12 (44%)
Neurological bleed/infarct/tumour3 (11%)
Comorbidities
Epilepsy13 (48%)
Supported ventilation7 (26%)
Oxygen dependence (day/night, or both)9 (33%)
Tracheostomy3 (11%)
Cardiac impairment10 (37%)
Scoliosis11 (41%)
Gastrostomy/jejunostomy fed15 (55%)
Immunodeficiency3 (11%)
Medication
Anti-epileptics13 (48%)
Anti-spasticity/dystonia medication11 (41%)
Anti-reflux medication13 (48%)
Prophylactic antibiotics9 (33%)
Immunoglobulin replacement1 (3%)
  • SMA, spinal muscular atrophy.